UNSPSC 51313102: Chlorcyclizine

This classification denotes a histamine-1 receptor antagonist with the molecular formula C18H21ClN2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M26C4IP44P, chemically known as piperazine, 1- (p-chloro-.alpha.-phenylbenzyl)-4-methyl-, monohydrochloride but generally known as chlorcyclizine, which bears US NIH Compound Identifier 2710. European Medicines Agency schedules Chlorcyclizine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06178MIG.

UNSPSC 51313102 Chlorcyclizine is a Commodity code that in practice covers pharmaceutical products and related health-care delivery goods procured by state and local health departments, county health agencies, and cooperative purchasing alliances — though the recent opportunities associated with this code do not directly reflect chlorcyclizine procurement itself. Instead, the tagged solicitations show state and local entities buying naloxone, generic multi-source pharmaceuticals, over-the-counter products, and direct-to-manufacturer prescription fulfillment services. The Seminole County, Florida IFB for naloxone and drug deactivation systems (IFB60459723LAS, due July 26, 2023) sought 1,900 units of naloxone and 800 deactivation systems annually with quarterly deliveries, requiring e-Procurement Portal submission, drug-free workplace certification, E-Verify compliance, workers' compensation and commercial general liability insurance, and a two-year initial term with one-year renewal option. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP (S1070000015802, due March 26, 2026) established multiple contracts for generic pharmaceuticals and OTC products across state and local facilities in Minnesota and Oregon, requiring vendors to supply through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, Morris & Dickson), maintain cGMP and Drug Supply Chain Security Act compliance, hold $5 million commercial general liability and $2 million network security and professional liability coverage, and accept a 3 percent administrative fee with performance penalties up to $1,500 per violation. The Texas Health and Human Services Commission issued a Request for Information (HHS0017013, posted April 3, 2026) to explore direct-to-manufacturer prescription contracting capabilities, seeking vendor experience with self-insured employer and state agency contracts, negotiated net pricing models, and value-based outcomes agreements.

Geographic activity centers on Florida, Texas, and the Minnesota–Oregon cooperative region, with state health departments, county health agencies, and multistate purchasing alliances as primary issuing bodies. The code shows mixed procurement intent — tactical purchases of specific pharmaceutical products (naloxone, generics, OTC items) alongside strategic exploration of supply-chain restructuring through direct-manufacturer relationships. Bidders should note that recent solicitations emphasize wholesaler-channel compliance, regulatory certification (cGMP, DSCSA, FDA), substantial insurance requirements, and administrative fee structures; responses typically require detailed product specifications, NDC codes, pricing flexibility across multiple formats, and electronic data interchange capability.